Silvia Schenone

Silvia Schenone

Auto-generated profile, based on publicly available information

Silvia Schenone

Pharmacy Department, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
IGIlaria Giacchello
Ilaria Giacchello
Francesca MusumeciFrancesca Musumeci
Francesca Musumeci
Ilaria D'AgostinoIlaria D'Agostino
Ilaria D'Agostino
CGChiara Greco
Chiara Greco
GGGiancarlo Grossi
Giancarlo Grossi
SSSilvia Schenone
Silvia Schenone
Background: Influenza is a seasonal disease that affects millions of people every year and has a significant economic impact. Vaccines are the best strategy to fight this viral pathology, but they are not always available or administrable, prompting the search for antiviral drugs. RNA-dependent RNA polymerase (RdRp) recently emerged as a promising target because of its key role in viral replication and its high conservation among viral strains. Discussion: This review presents an overview of the most interesting RdRp inhibitors that have been discussed in the literature since 2000. Compounds already approved or in clinical trials and a selection of inhibitors endowed with different scaffolds are described, along with the main features responsible for their activity. Results: RdRp inhibitors are emerging as a new strategy to fight viral infections and the importance of this class of drugs has been confirmed by the FDA approval of baloxavir marboxil in 2018. Despite the complexity of the RdRp machine makes the identification of new compounds a challenging research topic, it is likely that in the coming years, this field will attract the interest of a number of academic and industrial scientists because of the potential strength of this therapeutic approach.

1 July 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OBOlga Bruno
Olga Bruno
Chiara BrulloChiara Brullo
Chiara Brullo
FBFrancesco Bondavalli
Francesco Bondavalli
SSSilvia Schenone
Silvia Schenone
ARAngelo Ranise
Angelo Ranise
EBElisabetta Barocelli
Elisabetta Barocelli

30 March 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ARAlessandra Rossi
Alessandra Rossi
SSSilvia Schenone
Silvia Schenone
Adriano  AngelucciAdriano Angelucci
Adriano Angelucci
MCMartina Cozzi
Martina Cozzi
VCValentina Caracciolo
Valentina Caracciolo
Antonio GiordanoAntonio Giordano
Antonio Giordano
Medulloblastoma is the most common malignant brain tumor in children, and despite improvements in the overall survival rate, it still lacks an effective treatment. Src plays an important role in cancer, and recently high Src activity was documented in medulloblastoma. In this report, we examined the effects of novel pyrazolo‐[3,4‐d]‐pyrirnidine derivative Src inhibitors in medulloblastoma. By MTS assay, we showed that the pyrimidine derivatives indicated as S7, S29, and SI163 greatly reduce the growth rate of medulloblastoma cells by inhibiting Src phosphorylation, compared with HT22 nonneoplastic nerve cells. These compounds also halt cells in the G 2 /M phase, and this effect likely occurs through the regulation of cdc2 and CDC25C phosphorylation, as shown by Western blot. Moreover, the exposure to pyrimidine derivatives induces apoptosis, assayed by the supravital propidium iodide assay, through modulation of the apoptotic proteins Bax and Bcl2, and inhibits tumor growth in vivo in a mouse model. Notably, S7, S29, and SI163 show major inhibitory effects on medulloblastoma cell growth compared with the chemotherapeutic agents cisplatin and etoposide. In conclusion, our results suggest that S7, S29, and SI163 could be novel attractive candidates for the treatment of medulloblastoma or tumors characterized by high Src activity.—Rossi, A., Schenone, S., Angelucci, A., Cozzi, M., Caracciolo, V., Pentimalli, F., Puca, A., Pucci, B., La Montagna, R., Bologna, M., Botta, M., Giordano, A. New pyrazolo‐[3,4‐ d ]‐pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J . 24, 2881–2892 (2010). www.fasebj.org

1 December 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Mariangela BiavaMariangela Biava
Mariangela Biava
CBClaudio Battilocchio
Claudio Battilocchio
GPGiovanna Poce
Giovanna Poce
Alfonso SalvatoreAlfonso Salvatore
Alfonso Salvatore
SCSara Consalvi
Sara Consalvi
MAMaurizio Anzini
Maurizio Anzini

1 September 2008 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
SSSilvia Schenone
Silvia Schenone
SZSamantha Zanoli
Samantha Zanoli
Chiara BrulloChiara Brullo
Chiara Brullo
Emmanuele CrespanEmmanuele Crespan
Emmanuele Crespan
Giovanni MagaGiovanni Maga
Giovanni Maga
Protein kinases, either membrane-embedded receptorial or cytosolic non-receptorial ones, are important transducers of cell proliferation signals. In almost all tumor cells, the activity of some kinases is deregulated, either because of the presence of cancer-specific aberrant forms, or as a consequence of alterations in regulatory pathways, at the transcriptional or post-transcriptional level, which increase the activity of protein kinases with respect to normal cells. The study of the non-receptor tyrosine kinase Src plays a pivotal role in the field of the molecular genetics of cancer. The Src family of kinases (SFKs) comprises nine members, Src, Fyn, Yes, which are expressed in most tissues, and Blk,Yrk, Fgr, Hck, Lck and Lyn, which are more selectively expressed in particular tissues. To date, cellular (c-) Src has been implicated in the development of human cancer. Like oncogenic v-Src, activated mutants of c-Src can transform cells in culture and induce tumours in chickens. In addition, Src protein expression and/or activity is elevated in epithelial cancers, or cell lines derived from these, and there is often an association with advancement of disease or with malignancy. During the past decade, examples of tyrosine kinases inhibitors have been reported. Many of these compounds were highly active in vitro, but only a few demonstrated in vivo activity. These approaches led to the characterization of the PP1/PP2 derivatives as very strong and selective inhibitors of the c-Src family of kinases. Unfortunately, attempts to improve the biological profile of the latter compounds have so far met little success. Following these studies, some other inhibitors, possessing different chemical structures and interesting c-Src inhibitory activity, have been recently reported. Some of these molecules showed potent inhibition of tumor cell proliferation, which was due to the interference with the signalling pathway at the level of Src tyrosine kinase, providing proof-of-principle for the targeting of Src in anticancer chemotherapy.

11 November 2024 in Cancer Discovery
Verified
Journal Article
Closed access
SCSara Canato
Sara Canato
RSRahul Sarate
Rahul Sarate
SCSofia Carvalho-Marques
Sofia Carvalho-Marques
RSRaquel Maia Soares
Raquel Maia Soares
YSYura Song
Yura Song
CBCédric Blanpain
Cédric Blanpain
Stem cells (SC) and not progenitors (P) act as cells of origin of basal cell carcinoma (BCC). The mechanisms promoting BCC formation in SCs or restricting tumor development in Ps are currently unknown. In this study, we transcriptionally profiled SCs and Ps and found that Survivin, a pleiotropic factor that promotes cell division and inhibits apoptosis, was preferentially expressed in SCs. Using genetic gain- and loss-of-function mouse models, we showed that Survivin deletion in oncogene-expressing SCs prevents BCC formation. Survivin overexpression renders Ps competent to BCC formation by promoting cell survival and division while preventing apoptosis and differentiation. We identified Serum glucocorticoid–regulated kinase 1 (Sgk1) as a key downstream factor of Survivin and that its inhibition prevents BCC formation. This study uncovers the role and mechanisms by which Survivin regulates the competence of SCs to initiate BCC formation, promoting the survival of oncogene-expressing SCs and self-renewing division while restricting differentiation and apoptosis. Significance: This study identifies Survivin as a key regulator of the different ability of SCs and Ps to initiate skin cancer. Survivin expression in oncogene-targeted SCs is essential for their survival and self-renewal and to prevent their differentiation and apoptosis, allowing SCs and not Ps to initiate skin cancer.